Patent · US Expired

High affinity monoclonal antibody for recognizing the progesterone receptor (PR) and method for creating the antibody

US7569675B2 · kind B2 · utility

1Cited by
5References
9Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 11, 2002
Grant dateAug 4, 2009
Priority date
Expiry dateJun 25, 2025

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY10S436/813
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

A lagomorph derived monoclonal antibody for recognizing the progesterone receptor (PR) (clone SP2) with immunohistochemistry and methods for creating such an antibody are disclosed. No need of target retrieval in immunohistochemistry is their prominent advantage compared to currently available PR antibody. Furthermore, the very low background when the lagomorph derived monoclonal antibody is used in immunohistochemistry is also impressive. The immunohistochemistry comparative study with about fifty clinical specimens showed that the new PR antibody (clone SP2) antibody had favorable results when compared to mouse monoclonal antibody PR (clone 1A6), the best one in the current market. The PR antibody may prove of great value in the assessment of PR status in human breast cancer. Humanized versions of the PR antibody may provide therapeutic benefits.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.